Ontology highlight
ABSTRACT: Background
To review the experience and to evaluate the treatment plan of using helical tomotherapy (HT) for the treatment of cervical cancer.Methods
Between November 1st, 2006 and May 31, 2009, 10 cervical cancer patients histologically confirmed were enrolled. All of the patients received definitive concurrent chemoradiation (CCRT) with whole pelvic HT (WPHT) followed by brachytherapy. During WPHT, all patients were treated with cisplatin, 40 mg/m2 intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0).Results
The mean survival was 25 months (range, 3 to 27 months). The actuarial overall survival, disease-free survival, locoregional control and distant metastasis-free rates at 2 years were 67%, 77%, 90% and 88%, respectively. The average of uniformity index and conformal index was 1.06 and 1.19, respectively. One grade 3 of acute toxicity for diarrhea, thrombocytopenia and three grade 3 leucopenia were noted during CCRT. Only one grade 3 of subacute toxicity for thrombocytopenia was noted. There were no grade 3 or 4 subacute toxicities of anemia, leucopenia, genitourinary or gastrointestinal effects. Compared with conventional whole pelvic radiation therapy (WPRT), WPHT decreases the mean dose to rectum, bladder and intestines successfully.Conclusion
HT provides feasible clinical outcomes in locally advanced cervical cancer patients. Long-term follow-up and enroll more locally advanced cervical carcinoma patients by limiting bone marrow radiation dose with WPHT technique is warranted.
SUBMITTER: Hsieh CH
PROVIDER: S-EPMC2799427 | biostudies-literature | 2009 Dec
REPOSITORIES: biostudies-literature
Hsieh Chen-Hsi CH Wei Ming-Chow MC Lee Hsing-Yi HY Hsiao Sheng-Mou SM Chen Chien-An CA Wang Li-Ying LY Hsieh Yen-Ping YP Tsai Tung-Hu TH Chen Yu-Jen YJ Shueng Pei-Wei PW
Radiation oncology (London, England) 20091210
<h4>Background</h4>To review the experience and to evaluate the treatment plan of using helical tomotherapy (HT) for the treatment of cervical cancer.<h4>Methods</h4>Between November 1st, 2006 and May 31, 2009, 10 cervical cancer patients histologically confirmed were enrolled. All of the patients received definitive concurrent chemoradiation (CCRT) with whole pelvic HT (WPHT) followed by brachytherapy. During WPHT, all patients were treated with cisplatin, 40 mg/m2 intravenously weekly. Toxicit ...[more]